Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Moodys
Chubb
Chinese Patent Office
AstraZeneca
US Department of Justice
UBS
Fish and Richardson
McKesson

Generated: December 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 10,005,761

« Back to Dashboard

Which drugs does patent 10,005,761 protect, and when does it expire?

Patent 10,005,761 protects BRAFTOVI and MEKTOVI and is included in two NDAs.

This patent has sixty patent family members in forty-one countries.

Summary for Patent: 10,005,761
Title:Compounds and compositions as protein kinase inhibitors
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
Inventor(s): Huang; Shenlin (San Diego, CA), Jin; Xianming (San Ramon, CA), Liu; Zuosheng (San Diego, CA), Poon; Daniel (Piedmont, CA), Tellew; John (La Jolla, CA), Wan; Yongqin (Irvine, CA), Wang; Xing (San Diego, CA), Xie; Yongping (San Diego, CA)
Assignee: Array BioPharma Inc. (Boulder, CO)
Application Number:15/070,905
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 10,005,761

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-001 Jun 27, 2018 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF MELANOMA ➤ Try a Free Trial
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF MELANOMA ➤ Try a Free Trial
Array Biopharma Inc MEKTOVI binimetinib TABLET;ORAL 210498-001 Jun 27, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 10,005,761

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 077975 ➤ Try a Free Trial
Australia 2010286569 ➤ Try a Free Trial
Canada 2771775 ➤ Try a Free Trial
China 102725283 ➤ Try a Free Trial
China 103896921 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Julphar
QuintilesIMS
US Army
Cantor Fitzgerald
Teva
Johnson and Johnson
Covington
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.